Psilocybin-Assisted Therapy

Australian Health Authority To Allow Psilocybin And MDMA-Assisted Therapy For Depression, PTSD Beginning on July 1, 2023, medicines containing psilocybin and MDMA can be prescribed by specifically authorized psychiatrists to treat certain mental health conditions, such as ...

(Part three of a four-part series) Have a look at previous stories: Psychedelics And Treatment-Resistant Depression: An Overview Of COMPASS' Latest Trial Outcomes Psychedelics And Treatment-Resistant Depression: Reactions On Published Results atai Life Sciences (NASDAQ: ATAI) and COMPASS...

While psychedelics are still listed as Schedule I substances making them illegal under federal law, companies across North America are preparing to address patients’ needs in the hopefully upcoming psychedelics-assisted therapies (PAT) scenario. Ketamine Treatment Center Opens...

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) announced it will conduct two separate Phase 3 clinical trials to study psilocybin-assisted therapy on Treatment-Resistant Depression (TRD), reported Microdose.  Assuming positive results, Compass will...

Oregon's elected councilors in Philomath joined the debate on whether to offer their voters to “opt out” of Measure 109, the state-wide legalization project for the use of medical psilocybin. The legislation is set to begin ruling as of January 2023 and would make Oregon the...